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Abstract
 
B7-DC molecules are known to function as ligands on antigen-presenting cells (APCs), en-
hancing T cell activation. In this study, cross-linking B7-DC with the monoclonal antibody
sHIgM12 directly potentiates dendritic cell (DC) function by enhancing DC presentation of
major histocompatibility complex–peptide complexes, promoting DC survival; and increasing
secretion of interleukin (IL)-12p70, a key T helper cell type 1 promoting cytokine. Further-
more, ex vivo treatment of DCs or systemic treatment of mice with sHIgM12 increases the
number of transplanted DCs that reach draining lymph nodes and increases the ability of lymph
node APCs to activate naive T cells. Systemic administration of the antibody has an equivalent
effect on DCs transferred at a distant site. These findings implicate B7-DC expressed on DCs in
bidirectional communication. In addition to the established costimulatory and inhibitory func-
tions associated with B7-DC, this molecule can also function as a conduit for extracellular sig-
nals to DCs modifying DC functions.
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Introduction
 
B7-DC is a member of the extended B7 superfamily of co-
stimulatory molecules that have been shown to play an im-
portant role in the regulation of T cell activation and differ-
entiation (1, 2). Although B7-DC has less than 20%
sequence identity at the amino acid level with classical B7.1
and B7.2, it shares an immunoglobulin fold and globular
structure with other members of this family of costimula-
tory molecules. A homology search showed that B7-DC
has the highest homology to B7-H1 (38% identity, 48%
similarity; references 3 and 4). In addition to the high level
of homology, B7-DC and B7-H1 have both been shown
to bind PD-1, found on activated lymphocytes. B7-DC has
been shown to have potent costimulatory properties for na-
ive T cells in vitro (3). In these experiments, B7-DC fusion
protein costimulated higher levels of T cell proliferation
and IFN-
 
 
 
 expression than B7.1 costimulation. In a sepa-
rate study, however, B7-DC (PD-L2) was reported to in-
hibit cytokine production and cell cycle progression in pre-
viously activated T cells (5).
We had previously identified a naturally occurring hu-
man IgM antibody, sHIgM12, that specifically bound den-
dritic cells (DCs) and potentiated T cell activation and
proliferation in vitro (unpublished data). Furthermore,
B7-DC was identified as the ligand for sHIgM12 by DNA-
mediated gene transfer, antibody blocking studies, and
B7-DC knockout mice. The ability of IgM monomeric
fragments to inhibit the intact pentamers from promoting
T cell activation led us to investigate whether the antibody
had direct effects on DC function. To study whether bind-
ing of sHIgM12 to B7-DC affects DC biology; DCs were
treated in vitro with sHIgM12, polyclonal IgM control an-
tibody, or LPS. DCs treated in vitro were analyzed for their
ability to process and present a model antigen; and to se-
crete IL-12, a key immunomodulator, survive in culture in
the absence of supporting cytokines, and to migrate to
draining lymph nodes following adoptive transfer into syn-
geneic hosts. We find that an important aspect of B7-DC’s
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immune potentiating properties may be through the direct
modulation of DC biology. Cross-linking of B7-DC on
DCs increased antigen presentation and IL-12p70 produc-
tion in vitro. Furthermore, anti–B7-DC treatment increased
the survival of DCs in vitro and the migration of adoptively
transferred DCs reaching draining lymph nodes in vivo.
 
Materials and Methods
 
Mice and Reagents.
 
C57BL/6J and the green fluorescent
(GFP) transgenic C57BL/6-TgN(ACTbEGFP)1Osb transgenic
strains of mice were obtained from The Jackson Laboratory. B7-
DC knockout and litter mate control bone marrow was acquired
from Drew Pardoll, Johns Hopkins University. The knockout
mice were generated by disruption of the second exon of the B7-
DC gene on a 129/SvJ genetic background. The bone marrow
was derived from animals of mixed genotype, as the knockout
line is in the process of being backcrossed to C67BL/6. The B7-
DC status of DCs derived from the bone-marrow cells was con-
firmed by flow cytometry. B7-DC–deficient DCs did not express
epitopes recognized by rat anti-murine B7-DC-antibody (TY-
25) nor by DC-reactive human antibody sHIgM12.
The human monoclonal antibody sHIgM12 was isolated from
the serum of a patient with Waldenstrom Macroglobulinemia.
IgM antibody was purified from the serum by precipitation with
water and size-exclusion column chromatography. The prepara-
tion of antibody used in these experiments was greater than 90%
IgM by electrophoresis. A sharp light chain band was evident
upon electrophoresis, indicating the presence of a predominant
species of antibody, a finding consistent with our ability to obtain
a single unambiguous amino acid sequence from the prepared an-
tibody. Polyclonal human IgM antibody isolated in a similar fash-
ion was used for nonspecific control treatments. Appropriate
fluorophore-coupled anti-CD11c(HL-3) and anti-K
 
b
 
(AF6–88.5)
were obtained from BD Biosciences. 25D1.16 (anti-K
 
b
 
-SIIN-
FEKL) antibody was kindly provided by Dr. Jonathan Yewdell,
National Institutes of Health, Bethesda, MD (6). TY-25 anti–B7-
DC antibody is available from eBioscience. FITC-coupled goat
anti–human IgM (Jackson ImmunoResearch Laboratories) and
goat anti–mouse IgG secondary antibodies were obtained from
Accurate Chemical and Scientific. Chicken ovalbumin was ob-
tained from Sigma-Aldrich. The peptides were synthesized at the
Mayo Protein Core Facility, Mayo Clinic.
 
Generation of Immature and Matured DCs In Vitro.
 
DCs from
the bone marrow were isolated using an established protocol (7).
Briefly, bone marrow was isolated from the long bones of the
hind legs. Erythrocytes were lysed by treatment with ACK at
37
 
 
 
C. The remaining cells were plated at the density of 10
 
6
 
 per
ml in 6 well plates (Becton Dickinson) in RPMI (Hyclone) sup-
plemented with 10% FBS (Hyclone) and containing 10 ng/ml of
murine GM-CSF and 1 ng/ml of murine IL-4 (PeproTech). The
cells were incubated at 37
 
 
 
C with 5% CO2. After 2 d of culture
the cells were gently washed and replaced with RPMI-10 con-
taining the same concentration of GM-CSF and IL-4 for an addi-
tional 5 d.
 
Flow Cytometry.
 
Cells were washed with FACS
 
®
 
 buffer (0.5%
BSA and 0.1% sodium azide in PBS) and centrifuged into a 96-
well plate (Nunc). The indicated antibodies were added to the
wells for a 30 min incubation on ice. Samples requiring an incu-
bation with fluorochrome-conjugated secondary antibody were
washed twice before an additional 20 min incubation on ice. Af-
ter a subsequent three washes, cells were fixed with 1% parafor-
maldehyde and analyzed on a FACSCalibur™ (Becton Dickin-
son). Data was analyzed using CELLQuest™ Software (Becton
Dickinson).
 
Cytokine ELISA.
 
Day 7 bone marrow–derived DCs were
treated with sHIgM12, polyclonal IgM control antibody or LPS
at a final concentration of 10 
 
 
 
g/ml. The supernatants were col-
lected 72 h after stimulation and an IL-12p70 ELISA (BD Bio-
sciences) was performed according to manufacturer’s instruction.
The supernatant tested for each treatment groups was pooled
from six separate wells per experimental group. The experimental
groups were tested in triplicates and at numerous dilutions with
each demonstrating a similar profile.
 
Cellular Metabolism Studies.
 
DCs were plated on day 5 into
96-well plates at 2 
 
 
 
 10
 
4
 
 cells/well. Cells were cultured with
sHIgM12, A2B5 control antibody, or media to a final concentra-
tion of 10 
 
 
 
g/ml in RPMI-10 with GM-CSF and IL-4. In cy-
tokine withdrawal assays, DCs were washed and cultured in
RPMI-10 alone. After 1 h of culture, Alamar Blue (Biosource
International) was added to a final concentration of 10% (vol/
vol). Readings were taken at 24 h of culture on CytoFluor Mul-
tiplate Reader Series 4000 (PerSeptive Biosystems). The fluores-
cence plate reader was set to an excitation wavelength of 520 nm
and an emission reading of 590 nm. The data is representative of
three separate plates with each data point done in triplicate.
 
Adoptively-Transferred GFP DCs.
 
Bone marrow from green
fluorescent protein (GFP
 
 
 
) transgenic mice were used to derive
cultured GFP(
 
 
 
) DCs. SIINFEKL peptide-pulsed DCs were
treated with sHIgM12 or an isotype control antibody 16 h before
subcutaneous injection into the footpad. In the variant systemic
treatment experiment, untreated DCs were injected (day 0) into
the footpad of mice that had received three intravenous injections
(days –1, 0, 
 
 
 
1) with either sHIgM12 or pHIgM (10 
 
 
 
g). DCs
were isolated from the ipsilateral popliteal and inguinal lymph
nodes 48 h after transfer. Contralateral lymph nodes from both
treatment groups served as a control cohort. Samples were stained
with PE-conjugated CD11c antibody and analyzed by flow cy-
tometry. Isolated peptide-pulsed DCs were used as stimulators to
induce proliferation of OT-1 TCR Tg splenocytes.
 
Results and Discussion
 
The central role that DCs play in the initiation of an ef-
fective immune response is due in part to the costimulation
that is provided to naive T cells concurrent with antigen
presentation. Among the cohort of costimulatory mole-
cules known to be expressed by antigen-presenting cells,
the role of B7-DC in priming or maintenance of an im-
mune response is intriguing because of its relative DC spec-
ificity. There are contradictory observations, however,
about whether B7-DC ligation to its cognate receptor(s) on
T cell is stimulatory or inhibitory. Tseng et al. report that
B7-DC strongly costimulates naive T cell activation and
IFN-
 
 
 
 production (3). We likewise observed an increase in
T cell stimulatory capacity of wild-type DCs upon cross-
linking B7-DC (unpublished data). Latchman et al., how-
ever, report that B7-DC inhibits T cell activation and cy-
tokine production (5). Furthermore, high levels of B7-DC
also inhibited strong B7-CD28 costimulation. A possible
interpretation of enhanced T cell responses after DC treat-
ment with anti–B7-DC antibody is that the antibody
blocks the T cell inhibitory interaction between B7-DC 
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and PD-1. However, when we have looked directly, the
human IgM antibody sHIgM12 is not present on the sur-
face of treated DCs after washings routinely performed be-
fore the use of DCs in our in vitro T cell proliferation as-
says (unpublished data). Furthermore, a corollary of the
hypothesis that B7-DC mediates inhibition is that genetic
disruption of this pathway should increase T cell prolifera-
tion or activation. T cell proliferation, however, was not
enhanced upon induction with B7-DC deficient DCs.
DCs from these knockout mice, however, are still profi-
cient APCs after stimulation with anti-CD40 antibody.
The reports regarding the stimulatory or inhibitory role of
B7-DC may not be mutually exclusive as different experi-
mental conditions, such as the use of naive (3) versus acti-
vated (5) T cells and the existence of cognate receptors on
T cells other than PD-1, may explain the divergent find-
ings (8–10). Also, our observations that sHIgM12 antibody
does not remain bound to the surface of DCs in vitro does
not rule out the possibility that the antibody may play some
blocking role in vivo.
We have explored an alternative hypothesis. One possi-
bility is that cross-linking of B7-DC may induce functional
changes in DCs themselves. The implication of this view is
that the B7-DC molecule may be involved in cross talk be-
tween DCs and their environment.
 
Cross-linking B7-DC Directly Induces Functional Changes in
DCs.
 
The uptake and presentation of antigen is a basic
biological function of DCs. The effect of B7-DC cross-
linking on DC presentation of antigen was tested after in-
cubation with ovalbumin. DCs were concomitantly treated
with either the human monoclonal antibody sHIgM12 or
pHIgM control antibody. The processing and presentation
of ovalbumin by the treated DCs was evaluated with an an-
tibody (25D1.16) that specifically recognizes the immuno-
dominant ovalbumin peptide (SIINFEKL) in the context
of K
 
b
 
 MHC molecule (6). B7-DC cross-linking increases
the level of MHC-peptide complexes (K
 
b
 
-SIINFEKL) pre-
sented on the surface of wild-type DCs compared with un-
pulsed or pHIgM-treated DCs (Fig. 1 A, top panels).
sHIgM12 treatment of B7-DC–deficient DCs, however,
did not affect presentation of ovalbumin peptide relative to
pHIgM (Fig. 1 A, bottom panels). The difference in MHC
peptide complexes presented on the surface of sHIgM12-
versus pHIgM-treated DCs, was maximal at 24 h and de-
creased after 48 h of incubation (unpublished data). Levels
of K
 
b
 
 and D
 
b
 
 MHC molecules, however, were not differ-
ent between the treatment and control groups (unpub-
lished data).
Binding of 25D1.16 antibody to class I–peptide com-
plexes is strongly influenced by the cooperative binding
with Fc receptors to stabilize the low affinity idiotypic rec-
ognition of Kb-SIINFEKL (unpublished data). The levels
of Fc receptor (CD16/CD32) expressed on DCs, however,
were not different in both treatment and control groups
(unpublished data), indicating that the increased 25D1.16
binding truly reflects an increase in the limiting MHC–pep-
tide complexes elaborated on the cell surface. The levels of
accessory molecules involved in DC stimulation of an effec-
tive immune response were also tested. sHIgM12 cross-
linking of B7-DC did not significantly increase surface ex-
pression of MHC class II or CD80 and CD86 costimulatory
molecules (Fig. 1 B), or CD11c (unpublished data).
DC production of IL-12 was analyzed because this par-
ticular cytokine has a central role in stimulating the pro-
duction of IFN-
 
 
 
, a key factor in promoting Th1-type cel-
lular immunity (11, 12). An ELISA was performed on
culture supernatants to test for the presence of the active
form of IL-12. As shown in Fig. 2 A, sHIgM12 treatment
stimulated significantly higher levels of IL-12p70 released
by DCs than did LPS, a strong danger signal. Polyclonal
IgM treatment did not elicit detectable levels of IL-12p70.
Interestingly, the sHIgM12-induced secretion of IL-12p70
was first detectable 24 h after it could be detected in LPS-
activated DCs (unpublished data).
As cellular metabolism is an important parameter of DC
viability and differentiation, we examined the effects of B7-
DC cross-linking on DC biology by measuring DC metab-
olism of Alamar Blue under cytokine-deprived and -replete
conditions. As shown in Fig. 2 B, GM-CSF/IL-4 with-
drawal decreased metabolism in the cultures to 29% of the
level found in DCs cultured in cytokine-supplemented
media. Cross-linking B7-DC on DCs, however, resulted in
Figure 1. B7-DC cross-linking increases antigen presentation in vitro,
but does not increase expression of cell surface accessory molecules. (A)
Presentation of Kb-SIINFEKL complexes following treatment of ovalbu-
min protein-pulsed DCs with sHIgM12 (left panels) or pHIgM (right
panel) antibodies. Bone marrow–derived DCs from wild-type (top pan-
els) or B7-DC /  (bottom panels) mice were stained with 25-D1.16 anti-
body (unshaded) to detect specific MHC–peptide complexes. Shaded
histogram represents unpulsed DCs. (B) Immunostaining of ovalbumin-
pulsed DCs for MHC class II, CD80, or CD86 molecules after sHIgM12
(solid line) and pHIgM (hashed line) antibody treatment. Shaded histo-
gram represents staining isotype control antibody. 
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80% maintenance of metabolism levels 24 h after GM-
CSF/IL-4 withdrawal. Treatment of DCs with a control
IgM antibody that binds DCs, A2B5 (a monoclonal anti-
body that binds c-series ganglioside; reference 13), did not
significantly improve metabolism in the cultures compared
with media alone (33 vs. 29%). The higher rate of Alamar
Blue conversion after 24 h cytokine withdrawal in
sHIgM12 treatment groups directly correlated with higher
number of live trypan-blue and Annexin V–negative DCs
in these cultures compared with control cultures (unpub-
lished data). We do not rule out, however, the possibility
that sHIgM12 antibody treatment may also influence the
metabolic rates of individual living cells.
 
Antibody Enhances the Number of Adoptively Transferred
DCs that Reach Draining Lymph Nodes.
 
To further exam-
ine whether binding of sHIgM12 to B7-DC has a direct ef-
fect on DC viability, bone marrow–derived DCs from GFP
transgenic mice were treated in vitro before adoptive-trans-
fer into syngeneic, C57BL/6 mice. As shown in Fig. 3, A
and B, fivefold more GFP
 
 
 
CD11c
 
 
 
 DCs were recovered
from the draining popliteal and inguinal lymph nodes in
mice receiving sHIgM12-treated DCs compared with those
receiving pHIgM-treated DCs. The capacity of lymph node
immigrants to potentiate an immune response was tested by
concomitant treatment of the DCs with sHIgM12 and SI-
INFEKL peptide before adoptive transfer. In vitro treatment
of DCs with anti–B7-DC antibody not only increased the
number of DCs recovered from the draining lymph nodes,
but also increased by 10-fold the ability of these lymph node
DCs to induce an antigen-specific T cell response (Fig. 2 C).
While the finding that of ex vivo antibody treatment in-
fluences the ability of adoptively transferred DCs to reach
the draining lymph nodes has important therapeutic impli-
cations, we addressed the question of whether systemic ad-
ministration of the antibody could have similar affects. Un-
treated GFP
 
 
 
 DCs were adoptively transferred into the
footpad of naive animals to evaluate whether systemic ad-
ministration of the antibody sHIgM12 would influence the
number of DCs reaching draining lymph nodes. A fivefold
increase in GFP
 
 
 
 DCs were recovered from draining
lymph nodes in comparison to nodes recovered from mice
receiving systemic control IgM antibody treatment (Fig. 4).
This finding demonstrates that sIgM12 antibody adminis-
tered intravenously can influence the ability of distant DCs
to reach sites of T cell activation.
Together these data provide strong evidence that B7-
DC can function as a conduit for the communication of
signals directly to DCs from ligands in the environment.
We have demonstrated that cross-linking of B7-DC in-
duces changes in antigen processing, cell survival, and lym-
phokine production in DC populations grown in the ab-
sence of T cells. Direct modification of DC function is
observed in cells bearing genetic deficiencies in TLR-4 re-
ceptors, indicating that LPS is not a contributing factor in
these studies (unpublished data). Furthermore, we have
demonstrated that the ability of DCs to reach draining
lymph nodes after adoptive transfer into immunocompe-
tent hosts is enhanced by treatment with these antibodies.
One possible explanation of this finding is that antiapop-
totic effects of antibody treatment effectively raises the
number of surviving cells thereby increasing the number of
cells that make it to the lymph nodes. Another intriguing
possibility is that B7-DC interacts with cellular ligands that
provide signals that influence migration.
An important question is whether systemic administra-
tion of anti–B7-DC cross-linking antibody can potentiate
the response of resident DCs. The possibility that this is the
case is suggested by our recent findings that systemic treat-
ment of mice with sHIgM12 antibody enhances resistance
to transplantable B16 melanoma and potentiates T cell re-
sponses to systemically administered soluble protein (un-
Figure 2. Murine bone marrow–derived DCs secrete high levels of
IL-12p70 and exhibit prolonged survival in vitro following B7-DC cross-
linking. (A) Day 7 bone marrow–derived DCs were treated with
sHIgM12, polyclonal IgM control antibody or LPS at a final concentra-
tion of 10  g/ml. The supernatants were collected 72 h after stimulation
and an ELISA (BD Biosciences) was performed for the active fraction of
IL-12 cytokine. The experimental groups were tested in triplicates and at
numerous dilutions with each demonstrating a similar profile. (B) DC
metabolism after treatment was accessed by reduction of Alamar Blue af-
ter a 24 h incubation period. DCs were plated on day 5 into 96-well
plates at 2   104 cells/well. Cells were cultured with sHIgM12, A2B5
control antibody, or media with (solid) or without IL-4/GM-CSF
(hashed) supplementation. The data is representative of three separate
plates with each data point done in triplicate. 
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published data). Understanding how systemically adminis-
tered antibody mediates these important biological affects
may provide insights into how DC biology might be ma-
nipulated to gain advantage in a number of disease states
that intersect with the immune system.
The observed consequences of sHIgM12 binding to B7-
DC on DC biology is akin to recent data on TNF-related
activation-induced cytokine (TRANCE)-treated DCs.
Josien and colleagues observed that TRANCE-treated DCs
were better inducers of primary and secondary T cell re-
sponses in vivo (14). Furthermore, TRANCE-receptor ac-
tivator of NF-
 
 
 
B (RANK) interaction on DCs increased
the in vivo longevity and subsequent migration of DCs to
the draining lymph node by 5–10 fold (14). Although sig-
naling through TNFR superfamily members, like CD40
and RANK, is known to modulate DC biology, the
downstream consequences of B7 superfamily binding has
not been established. There is data to suggest a regulatory
role of B7.1 and B7.2 molecules expressed on B cells and
lymphomas. Signaling through these costimulatory mole-
cules was reported to regulate B cell proliferation, antibody
production, and Bcl-X(L) expression in these cells (15, 16).
Our data suggests that ligation of B7-DC on DCs has
similar regulatory properties. To our knowledge, the role of
B7 superfamily members in regulating DC biology has not
been previously reported. In contrast to classical B7.1 and
B7.2, murine B7-DC has a very short cytoplasmic domain
(4 amino acids) that would not be expected to associate with
signaling intermediates. A possible mechanism for B7-DC–
mediated signaling in DCs is through the interaction with a
coreceptor that contains intracellular signaling motifs. The
presence of two charged amino acids within the transmem-
brane domain of murine B7-DC suggests a potential binding
partner (3). The association of receptor subunits via charged
amino acids within the transmembrane region is seen in a
number of immune receptor complexes (i.e., TCR-CD3,
BCR-Ig 
 
 
 
/
 
 
 
, and Ly49-DAP12) on lymphocytes.
Figure 3. Anti-B7.DC treatment enhances potency and number of
adoptively-transferred DCs recovered from draining lymph node. (A)
Flow cytometric analysis, and (B) enumeration of CD11c ; GFP  cells in
draining lymph nodes of treated mice. Treatment with sHIgM12 (solid);
or pIgM (hashed). Isolation of cells from ipsilateral (dark); or contralateral
(light) lymph nodes. (C) Proliferation of OT-I TCR Tg splenocytes after
incubation with isolated DCs. Ovalbumin-pulsed DCs were treated be-
fore adoptive transfer with either sHIgM12 (filled) or pIgM (open) con-
trol. Each group was performed in triplicate. The data is representative of
three independent experiments.
Figure 4. Systemic sHIgM12 treatment increases the number of adop-
tively transferred DCs recovered from the draining lymph node. Un-
treated GFP  DCs were injected (day 0) into the footpad of mice that had
received intravenous injections of sHIgM12 or pHIgM on days –1, 0,
 1. Ipsilateral and contralateral draining lymph nodes were recovered 48 h
later. Staining and flow cytometric analysis was performed as described in
Materials and Methods. 
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Recently, DCs have also been shown to express activat-
ing surface receptors that associate with signaling corecep-
tors components. Fc
 
 
 
R and TREM-2 are immunoglobu-
lin superfamily members, that require the association of
Fc
 
 
 
R-associated 
 
 
 
 chain and DAP12, respectively, to acti-
vate DCs (17, 18). Interestingly, TREM-2/DAP12 pro-
motes a partial activation of DCs through nuclear factor
(NF)-
 
 
 
B–independent up-regulation of classical matura-
tion markers (MHC class II, CD80, and CD86) without
concurrent secretion of IL-12 (18). In contrast, cross-link-
ing of B7-DC mobilizes IL-12 secretion without increasing
surface maturation marker. It is interesting to speculate
whether DCs may express a series of surface receptors that
have distinct, perhaps complementary, function depending
upon the immunological context.
In conclusion, the key role that DCs play in regulating
the immune response has made them a focal point for ther-
apeutic intervention in a number of clinical settings (19–
23). Our observations that B7-DC cross-linking in vitro
has a profound effect on DC viability, migration, and IL-12
production provide a rational scheme for interventions that
require ex vivo DC manipulation. Furthermore, it will be
interesting to see whether other signaling pathways that al-
ter DC biology, such as CD40 and RANK, will have addi-
tive or synergistic effects when targeted in conjunction
with B7-DC.
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